Dexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care for CGM use by people with Type 2 diabetes not using insulin around the world. Showed use of Dexcom ...
Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use ...
Zacks Investment Research on MSN
Dexcom reports positive CONNECT data for non-insulin diabetes
DexCom, Inc. DXCM recently announced positive results from its CONNECT randomized controlled trial, demonstrating that use of the Dexcom G7 continuous glucose monitoring (CGM) system significantly ...
DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results